MIT’s Laboratory for Computational Physiology curates one of the world’s largest critical-care datasets, comprising de-identified EHRs for over 65,000 ICU admissions and 200,000 emergency-department encounters. PGxAI harnesses this rich clinical resource, together with MIT’s expertise in machine learning and biomedical informatics, to train and validate generative models that link multi-omics biomarkers to drug response and adverse-event risk.

Hyperscale cloud provider operating 40 global regions and multiterabit backbone networks, unveiled at Google Cloud Next ’24. Through the top-tier Google for Startups Cloud Program, PGxAI harnesses high-performance compute clusters and TPU accelerators for large-scale model training and secure deployment.

Azure’s trusted infrastructure spans 60 + regions and 300 + datacenters, the broadest footprint of any public cloud. Via the Microsoft for Startups Founders Hub, PGxAI leverages Azure AI tooling and DevOps pipelines to scale R&D and CI/CD globally.

Market leader holding ~92 % of the data-center GPU segment and driving record annual revenue above US $115 billion in 2024. Membership in NVIDIA Inception provides PGxAI with GPU credits and deep-learning expertise to accelerate LLM and multi-omics model development.

A global top-50 research university, UBC attracted CA $ 892.8 million in external funding across 9,992 projects in FY 2023/24 and counts eight Nobel laureates among its faculty. Canada’s largest medical school and network of teaching hospitals serve a diverse, 30-million-patient catchment, driving breakthroughs in genomics, oncology, and population health. PGxAI collaborates with UBC on a patient real-world study that evaluates AI-guided genotype–phenotype predictions and their impact on prescribing outcomes.

Global data-platform company whose technology manages >1 billion patient records worldwide and underpins thousands of hospital EHRs. PGxAI deploys its multi-omics engine on InterSystems IRIS for Health to deliver sub-second genomic recommendations inside interoperable clinical workflows.

CAP-accredited and CLIA-certified, Dynamic DNA operates a state-of-the-art molecular diagnostics facility that keeps all sequencing and genotyping in-house, ensuring stringent quality control and rapid turnaround. The lab now supporting clinical pharmacogenetics, ancestry testing, and specialised psychedelic-safety panels. Through this partnership, PGxAI couples Dynamic DNA’s high-throughput wet-lab capacity with its AI-powered interpretation engine.

Privacy-first genomics company operating what it bills as the world’s largest marketplace for DNA analysis apps and offering CLIA-certified whole-genome sequencing shipped to all 50 states. The platform combines end-to-end sample logistics, HIPAA-compliant cloud storage, and more than 100 third-party health reports. PGxAI integrates with Sequencing.com’s sequencing pipeline and data APIs to deliver turnkey pharmacogenomic testing for U.S. clients.

Premier technology law firm with 1,100 + attorneys across 17 offices and a client base exceeding 300 public and 3,000 private companies; ranked a “Recommended Firm” for patents by WIPR USA 2024. PGxAI relies on Wilson Sonsini for strategic counsel on intellectual-property protection and complex licensing.